In Reply We agree with Drs Redington and Caldarone that many animal and human studies have shown that a single or few (≤5) short episodes of remote ischemic preconditioning (typically 5 minutes of limb ischemia followed by 5 minutes of reperfusion) are protective for many organs (including the heart, brain, and kidney) with few reported adverse effects.
However, few studies have examined the long-term effects of repeated episodes of remote ischemic preconditioning, and this is what we referred to in our Editorial that the effects of multiple episodes of remote ischemic preconditioning, which patients may be exposed to if remote ischemic preconditioning is widely used, are unclear.
For example, the study by suggested that in addition to tachyphylaxis (ie, increased tolerance to the effect of an intervention), repeated episodes of limb ischemia may have unfavorable consequences for collagen and systemic effects mediated via matrix metalloproteinases. The authors concluded that the benefits of protection against ischemia may be found at low doses (ie, low number and duration of preconditioning episodes), but these benefits may be lost and adverse effects may occur (collagen damage) at high doses.
In addition, remote ischemic preconditioning may have limited utility for cardioprotection in 2 large populations (elderly patients and those with diabetes) at high risk for cardiovascular diseases, 5 and may be associated with higher risk for atrial fibrillation, even when used at the conventional dose (5-minute episodes of ischemia/reperfusion repeated 5 times) before coronary artery bypass graft surgery.
6 Therefore, even though we share the enthusiasm of Redington and Caldarone for the promise of remote ischemic preconditioning for organ protection, investigators in the field should examine potential long-term harmful effects to various organs, including the heart, particularly when hyperconditioning is used. 1 A recent internal subanalysis of these data revealed anomalies, which triggered an investigation and an admission of fabricated results by Anna A. Ahimastos, PhD, who is both the first and corresponding author and was responsible for data collection and integrity for the article. No other coauthors were involved in this misrepresentation. In particular, the data collected at the Townsville and Brisbane sites remain valid. Given the current indications for ramipril, we do not believe that patients have been adversely affected. All authors recognize the seriousness of this issue and apologize unreservedly to the editors, reviewers, and readers of JAMA. A system of good clinical practice was in place; however, clinical governance and audit procedures will be reviewed and strengthened to minimize the chance of possible recurrence of such behavior. We are also in the process of examining other studies for which Dr Ahimastos had oversight of data collection and integrity.
We sincerely regret that this study has been compromised. We feel deeply disappointed and let down by this
